aibioMCRB Seres Therapeutics, Inc.
Seres Therapeutics (MCRB) news
Top story · Aug 4, 2026 · SEC filing 8-K
Seres Therapeutics signs a material agreement
Lease Amendment and Termination Agreement On July 31, 2026 (the “Execution Date”), Seres Therapeutics, Inc.
Latest Seres Therapeutics news
We have not published a story on Seres Therapeutics yet. When there is news, it will appear here.
Seres Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $789,000 | $0 |
| Research and development | $49.1 million | $64.6 million |
| Net income (loss) | $5.7 million | $136,000 |
| Cash from operations | $1.1 million | -$148.6 million |
| Cash and equivalents | $45.8 million | $30.8 million |
Questions about Seres Therapeutics
What is the ticker symbol of Seres Therapeutics?
Seres Therapeutics, Inc. trades under the ticker MCRB on NASDAQ.
Where is Seres Therapeutics listed?
Seres Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1S90; LS:A413XF.
What is the SEC CIK of Seres Therapeutics?
The SEC Central Index Key (CIK) for Seres Therapeutics, Inc. is 1609809. Its filings are on SEC EDGAR.
How many shares does Seres Therapeutics have outstanding?
9,941,261 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Seres Therapeutics listed under?
Our directory records Seres Therapeutics, Inc. under United States.
What does Seres Therapeutics do?
Our directory classifies Seres Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Seres Therapeutics?
The ISIN recorded for Seres Therapeutics, Inc. is US81750R2013.
Does aibio.space cover Seres Therapeutics?
aibio.space lists Seres Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Seres Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was Seres Therapeutics's revenue last year?
$789,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Seres Therapeutics profitable?
Seres Therapeutics, Inc. reported net income of $5.7 million for the fiscal year ended Dec 31, 2025, and generated $1.1 million of cash from operations, per its annual report to the SEC.
How much does Seres Therapeutics spend on research and development?
$49.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Seres Therapeutics have?
$15.6 million in cash at Jun 30, 2026, per its 10-Q.
What is Seres Therapeutics's market cap?
We do not publish live share prices. In its annual report, Seres Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $71.9 million as of Jun 30, 2025.
Is Seres Therapeutics a smaller reporting company?
SEC records list Seres Therapeutics, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company.
Investor discussion: Seres Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,9.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,7.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Seres Therapeutics, Inc.
- CIK
- 1609809
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- MCRB (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Phone
- 617 945 9626
- Shares outstanding
- 9,941,261 as of 2026-08-03 (10-Q filed 2026-08-05)
- Former names
- Seres Therapeutics, Inc.; Seres Health, Inc.
Recent filings
Listing details
- Company
- Seres Therapeutics, Inc.
- Ticker
- MCRB
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US81750R2013
- Other listed symbols
- GETTEX:1S90; LS:A413XF
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction